Takara Bio Inc
Takara Bio Inc., together with its subsidiaries, engages in the businesses of reagents, equipment, contract services, and genetic medicine in Japan, China, the rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including reagents needed for genetic and cellular research, PCR instruments, cellular analysis devices, and in vitro diagnostics for… Read more
Takara Bio Inc (TF2) - Total Liabilities
Latest total liabilities as of September 2025: €29.21 Billion EUR
Based on the latest financial reports, Takara Bio Inc (TF2) has total liabilities worth €29.21 Billion EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Takara Bio Inc - Total Liabilities Trend (2014–2025)
This chart illustrates how Takara Bio Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Takara Bio Inc Competitors by Total Liabilities
The table below lists competitors of Takara Bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tianjin Jiuri New Materials Co Ltd
SHG:688199
|
China | CN¥1.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥114.81 Million |
|
Timberland Bancorp Inc
NASDAQ:TSBK
|
USA | $1.74 Billion |
|
Primis Financial Corp
NASDAQ:FRST
|
USA | $3.62 Billion |
|
APG SGA SA
SW:APGN
|
Switzerland | CHF93.01 Million |
|
Hunan Resun Co Ltd
SHE:001218
|
China | CN¥802.14 Million |
|
ASRock Inc
TW:3515
|
Taiwan | NT$11.55 Billion |
|
Jiangsu Holly Corp
SHG:600128
|
China | CN¥3.66 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Takara Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Takara Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Takara Bio Inc (2014–2025)
The table below shows the annual total liabilities of Takara Bio Inc from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | €9.49 Billion | +0.19% |
| 2024-03-31 | €9.47 Billion | -43.46% |
| 2023-03-31 | €16.75 Billion | -14.76% |
| 2022-03-31 | €19.65 Billion | +27.18% |
| 2021-03-31 | €15.45 Billion | +83.54% |
| 2020-03-31 | €8.42 Billion | +21.21% |
| 2019-03-31 | €6.95 Billion | +0.73% |
| 2018-03-31 | €6.89 Billion | -3.67% |
| 2017-03-31 | €7.16 Billion | +10.43% |
| 2016-03-31 | €6.48 Billion | -4.44% |
| 2015-03-31 | €6.78 Billion | +26.24% |
| 2014-03-31 | €5.37 Billion | -- |